Bargain hunters pounced on this beaten-down biotech stock last month. Here's why.
News & Analysis: Heron Therapeutics
Its non-opioid painkiller gets a rejection over non-clinical issues.
Heron Therapeutics and Novavax are two key healthcare stocks to watch this month.
AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.
Heron Therapeutics and Intercept Pharmaceuticals are too cheap to ignore right now.
Disruptions in clinical trials and delayed regulatory decisions could slow the rate of new drug approvals.
Risk-taking investors flock to biotech for its constant flow of events that can spike or crush the stock prices of the companies developing the latest therapies.
These two biotech stocks are poised for big gains next year.
A high-risk transformative move sent one of these stocks lower.
You should never blindly follow the crowd, but it pays to watch what the biggest and brightest on Wall Street are doing.